A guide to venous Thromboembolism risk factor assessment, Journal of Thrombosis and Thrombolysis, vol.9, issue.3, pp.253-262, 2000. ,
DOI : 10.1023/A:1018770712660
Venous thromboembolism following major orthopedic surgery: review of epidemiology and economics, AmJ Health Syst Pharm, vol.58, issue.2, pp.4-13, 2001. ,
Risk factors for venous thrombotic disease, Thromb Haemost, vol.82, pp.610-619, 1999. ,
Risk factors in venous thromboembolism, Thromb Haemost, vol.86, pp.395-403, 2001. ,
Identification of Candidates for Prevention of Venous Thromboembolism, Seminars in Thrombosis and Hemostasis, vol.23, issue.01, pp.55-56, 1997. ,
DOI : 10.1055/s-2007-996071
Strikes in French public transport and resistance to activated protein C, The Lancet, vol.347, issue.8995, p.206, 1996. ,
DOI : 10.1016/S0140-6736(96)90393-1
Risk factors in venous thromboembolism, Thromb Haemost, vol.86, pp.395-403, 2001. ,
Pr??vention de la maladie thromboembolique en orthop??die et traumatologie, Annales Fran??aises d'Anesth??sie et de R??animation, vol.24, issue.8, pp.871-889, 2005. ,
DOI : 10.1016/j.annfar.2005.06.007
Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in medical patients with enoxaparin (MEDENOX) trial, The American Journal of Cardiology, vol.86, issue.12, pp.48-52, 2000. ,
DOI : 10.1016/S0002-9149(00)01481-8
Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study), Vascular Medicine, vol.7, issue.4, pp.269-273, 2002. ,
Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial, BMJ, vol.332, issue.7537 11, pp.325-354, 2006. ,
A prospective observational study of a cohort of outpatients with an acute medical event and reduced mobility: incidence of symptomatic thromboembolism and description of thromboprophylaxis practices, Journal of Internal Medicine, vol.91, issue.24, pp.168-176, 2006. ,
DOI : 10.1007/s11239-004-0208-6
URL : https://hal.archives-ouvertes.fr/hal-00281342
Incidence and Prophylaxis of Deep Venous Thrombosis in Outpatients with Injury of the Lower Limb, Pathophysiology of Haemostasis and Thrombosis, vol.23, issue.1, pp.20-26, 1993. ,
DOI : 10.1159/000216905
Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilisation of the leg, The Lancet, vol.346, issue.8973, pp.459-61, 1995. ,
DOI : 10.1016/S0140-6736(95)91320-3
Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast, Thrombosis Research, vol.105, issue.6, pp.477-80, 2002. ,
DOI : 10.1016/S0049-3848(02)00059-2
Use of the Low-Molecular-Weight Heparin Reviparin to Prevent Deep-Vein Thrombosis after Leg Injury Requiring Immobilization, New England Journal of Medicine, vol.347, issue.10, p.726, 2002. ,
DOI : 10.1056/NEJMoa011327
Incidence and risk factors for venous thromboembolism in patients with nonsurgical isolated lower limb injuries, The American Journal of Emergency Medicine, vol.25, issue.5, pp.502-510, 2007. ,
DOI : 10.1016/j.ajem.2006.09.012
URL : https://hal.archives-ouvertes.fr/hal-00281333
Prevention of venous thromboembolism in patients with immobilization of the lower extremities: a meta-analysis of randomized controlled trials, Journal of Thrombosis and Haemostasis, vol.9, issue.1, pp.1093-1098, 2008. ,
DOI : 10.1111/j.1538-7836.2007.02570.x
Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization " Department of Surgery and Orthopaedic Surgery, Viecuri Medical Centre of Northern Limburg BL. marktestroote@yahoo.com : Cochrane Database Syst Rev Comparing consensus guidelines on thromboprophylaxis in orthopedic surgery, CD006681. 22, pp.5912-678, 2008. ,
NCT00843492?order=1 droit d'opposition à la transmission de vos données couvertes par le secret professionnel susceptibles d'être utilisées dans le cadre de cette recherche et d'être traitées en contactant le centre de coordination ,
Comité d'Ethique des Centres d'Investigation Clinique de l'Inter région Rhône-Alpes-Auvergne) a donné un avis favorable à la réalisation de cette recherche ,
Amélioration Pas d'amélioration Traitement préventif Pas de traitement Mineurs : Obésité Insuffisance respiratoire Insuffisance cardiaque Pilule Insuffisance veineuse Déshydratation Périmètre de marche > 10 m Nuls : Tabac Contre indications HBPM : Clairance Créatinine<30 Grossesse 1 er trimestre Allergie vraie Variables recueillies à J0 Accès par mot de passe puis : N° centre??????? N° patient :?????? Sexe ,
Type d'immobilisation A B Prophylaxie par HBPM : Oui Non Si Oui : menu déroulant Tinzaparine sodique (Innohep®) 4500UiAntiXa/0,45ml /J Enoxaparine (lovenox®) 40mg, J Fondaparinux (Arixtra®), vol.2 ,
Normal Anormal Pas d'appui ,